EULAR 2021: Expert Insights on Axial Spondyloarthritis and Axial Psoriatic Arthritis*

Download All
June 2-5, 2021; Virtual
Get up to date on the latest clinically important data on axial spondyloarthritis and axial psoriatic arthritis with Capsule Summaries and expert-authored commentaries covering key studies from EULAR 2021.

EULAR 2021: Expert Insights on Axial Spondyloarthritis and Axial Psoriatic Arthritis

Capsule Summary Slidesets

Most DMARDs, including methotrexate, biologics, and JAK inhibitors, can be continued when the BNT162b2 mRNA COVID-19 vaccine is given.

Released: July 30, 2021

In this real-world cohort, patients with axial spondyloarthritis demonstrated higher rates of uveitis and IBD, reported greater overall and spine pain vs patients with axial psoriatic arthritis.

Released: July 26, 2021

MRI criteria including bone marrow edema in ≥4 vertebral corners (or fewer if other lesions present) found to be consistent with rheumatologic diagnosis.

Released: July 28, 2021

SPARCC method with transitional slice and subsequent 4 slices optimal to evaluate for lesions in SIJ in patients with axSpA.

Released: August 3, 2021

Although disease activity improved with ixekizumab treatment regardless of sex, time to improvement and peak response was longer for females vs males.

Released: July 26, 2021

Even without flare, withdrawal of CZP associated with increased ASDAS, CRP, BASDAI, and fecal calprotectin.

Released: August 3, 2021

Across SpA-specific assessments, patients with primary or secondary fibromyalgia demonstrated higher PRO scores vs patients with axSpA/PsA alone.

Released: July 26, 2021

CSI ≥40 significantly associated with higher ASQoL score, higher ASDAS score, and female sex.

Released: July 28, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue